Cullinan Oncology reports $468.3M cash as of Dec 31, 2023; runway into H2 2026

As of December 31, 2023, Cullinan Oncology, Inc.’s (the “Company’s”) unaudited cash, cash equivalents, investments, and interest receivable totaled $468.3 million. Consistent with prior guidance, the Company expects its cash resources to provide runway into the second half of 2026 based on its current operating plan. The Company has not yet completed its quarter-end financial close process for the quarter ended December 31, 2023. This estimate of the Company’s cash, cash equivalents, investments, and interest receivable as of December 31, 2023 is preliminary, has not been audited and is subject to change upon completion of the Company’s financial statement closing procedures.